Mittal Patel, APN

Mittal Patel practices at Hudson-Essex Allergy in Jersey City, New Jersey.

Mittal Patel's NPI, 1093229619, was assigned on November 17, 2017. Mittal Patel holds New Jersey license 26NJ00776600.

Mittal Patel's primary practice is Hudson-Essex Allergy, at 33 Hudson St, Jersey City, NJ 07302 in Hudson County. The practice phone is (973) 759-5842.

Mittal Patel's primary practice is Hudson-Essex Allergy in Jersey City, New Jersey. The medical group on file is Atlantic Health Partners. Dmand AI also links Mittal Patel to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mittal Patel practices, 3 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Mittal Patel's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Mittal Patel is licensed in New Jersey.

CMS data shows 16 Medicare services from Mittal Patel across 1 procedure code in 2021, all of them office visits, for 18 Medicare patients. Medicare paid $972 for them. Every service was in an office.

CMS counts 18 Medicare patients who saw Mittal Patel in 2024. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.44, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mittal Patel's median patient age at 26, with 51% women.

In 2024, Mittal Patel wrote 129 Medicare Part D claims for 35 patients. 78% of them were for generic drugs. CMS names the drug for 83 of them, across 4 drugs with 11 or more claims each, at $4,062 in total drug cost. In 2022, CMS named 23 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Mittal Patel for performance year 2024, reported as part of a group. Mittal Patel accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 41 general payments to Mittal Patel from 20 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Optinose US, Inc. paid the most, $118.